USPH:NYSEU.S. Physical Therapy, Inc. Analysis
Data as of 2026-09-01 - not real-time
$77.74
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
U.S. Physical Therapy, Inc. is priced at $77.74, and its moving averages give no clean directional read — the structure is neutral. Across the trailing 30 sessions it gained 4.5%. Momentum indicators put RSI at 50.3 (neutral) with MACD reading bearish. Price has been bracketed by support at $70.64 and resistance at $83.43.
The shares look fair, trading on 457.3 times earnings above a sector average of 30.4. Sell-side targets cluster 22.2% above the current quote. Revenue is growing at 8.5% on a 4.0% profit margin. The 2.34% dividend yield looks stretched against payout coverage.
On a 1-10 scale the risk profile lands at 6 — elevated. With 30-day volatility of 29.0%, a beta of 0.67 and a maximum drawdown of 36.7%, position sizing matters here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
All three time horizons resolve to hold, carrying 3/10 conviction.
The shares look fair, trading on 457.3 times earnings above a sector average of 30.4. Sell-side targets cluster 22.2% above the current quote. Revenue is growing at 8.5% on a 4.0% profit margin. The 2.34% dividend yield looks stretched against payout coverage.
On a 1-10 scale the risk profile lands at 6 — elevated. With 30-day volatility of 29.0%, a beta of 0.67 and a maximum drawdown of 36.7%, position sizing matters here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
All three time horizons resolve to hold, carrying 3/10 conviction.
Top Market Events
US Physical Therapy Inc USPH posts record Q2 visits per clinic, raises 2025 EBITDA guidance to $93-$97 million, and...Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter.The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 3/10
Key Factors
- Trading above the 200-day average of 75.40
- MACD momentum is negative
- Maximum drawdown of 36.7%
Medium Term
1–3 yearsNeutral
Model confidence: 3/10
Key Factors
- P/E of 457.3 versus sector average of 30.4
- Dividend yield of 2.34% looks stretched against payout coverage
- Trading above the 200-day average of 75.40
Long Term
> 3 yearsNeutral
Model confidence: 3/10
Key Factors
- P/E of 457.3 versus sector average of 30.4
- Dividend yield of 2.34% looks stretched against payout coverage
- Analyst targets imply +22.2% versus the current price
Key Metrics & Analysis
Financial Health
Revenue Growth8.50%
Profit Margin4.01%
P/E Ratio457.3
ROE6.51%
ROA4.10%
Debt/Equity50.32
P/B Ratio2.6
Op. Cash Flow$83.0M
Free Cash Flow$41.3M
Industry P/E30.4
Technical Analysis
TrendNeutral
RSI50.3
Support$70.64
Resistance$83.43
MA 20$79.00
MA 50$75.08
MA 200$75.40
MACDBearish
VolumeDecreasing
Fear & Greed Index93.04
Valuation
Fair Value$26.36
Target Price$95.00
Upside/Downside22.20%
GradeFair
TypeBlend
Dividend Yield2.34%
Risk Assessment
Beta0.67
Volatility29.00%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.